Application of acetyl bufalin in preparation of antitumor drugs

An anti-tumor drug, the technology of acetyl bufalin, applied in the field of biomedicine, can solve the problems of poor anti-cancer effect, unclear anti-cancer mechanism and target, and achieve the effect of good inhibitory effect

Active Publication Date: 2018-08-03
WENZHOU MEDICAL UNIV +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, some studies have reported that bufalin has a certain anticancer effect,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of acetyl bufalin in preparation of antitumor drugs
  • Application of acetyl bufalin in preparation of antitumor drugs
  • Application of acetyl bufalin in preparation of antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0024] The synthesis of embodiment 1 acetylbufafen

[0025] Bufalin (15 mg, 0.0388 mmol) and triethylamine (0.39 mmol) were dissolved in dry dichloroethane (1 mL), then acetyl chloride (0.39 mmol) was added, and the reaction mixture was stirred at room temperature for 19 hours. The solvent was spin-dried, and then column chromatography was performed on a silica gel column (DCM / MeOH=50:1to20:1) to obtain the product (17 mg, 100% yield) as a pale yellow solid.

[0026] The reaction formula is as follows:

[0027]

[0028] Product characterization data are as follows:

[0029] 1 H NMR (400MHz, CDCl 3 )δ7.82(dd, J=9.6,4.0Hz,1H),7.22(s,1H),6.26(d,J=9.6Hz,1H),5.07(s,1H),2.49-2.40(m,1H ),2.26-2.15(m,1H),2.09-1.99(m,4H),1.94-1.81(m,2H),1.80-1.35(m,18H),1.27(s,3H),0.69(s,3H ); 13 C NMR (100MHz, CDCl3) δ170.7, 162.3, 148.6, 146.7, 122.6, 115.3, 85.4, 70.4, 51.3, 48.4, 42.4, 40.9, 36.8, 35.9, 35.2, 32.8, 30.5, 30.5, 28.7, 26.4, 25.1, 2 , 21.5, 21.4, 21.3, 16.5; ESI-HRMS: calcd....

Example Embodiment

[0030] Example 2 Acetylbufafamide inhibits NSCLC cell proliferation

[0031] Three human non-small cell lung cancer cell lines PC-9, A549, and H460 were selected, and the effects of bufafolin (Bu) and acetylbufafolin (Ac-Bu) on the proliferation of these cells were observed by MTT experiment. NSCLC cells were seeded in a 96-well plate (cell concentration: 5000 / well), and 100ul RPMI1640 culture solution was added to each well for overnight culture. After the cells adhered to the wall, the medium was changed, and different concentration gradients of bufafalin and acetylbufafalin were added. The same amount of DMSO was added to each group. After culturing for 48 hours, add MTT solution, continue culturing for 4 hours, discard the supernatant, add DMSO to dissolve, detect the absorbance value, and determine the IC50. The result is as figure 1 Shown: the inhibitory effect of acetylbufalin to PC-9 cell proliferation is improved about 5 times than bufalin ( figure 1 A), acetylbufa...

Example Embodiment

[0032] Example 3 Acetylbufalin induces apoptosis of NSCLC cells.

[0033] We used the Hoechst 33258 apoptosis staining kit to stain the nucleus, and judged the apoptosis by observing the color of the nucleus. The results were as follows: figure 2 As shown, it was found that the nuclei color of PC-9 cells changed from normal blue to bright blue after different concentrations of acetylbufafoat (100nM, 200nM, 400nM) acted on PC-9 cells for 24h, indicating that apoptosis occurred in the cells, and as the concentration increased High apoptosis is more obvious.

[0034] We used Annexin V-FITC / PI double-staining flow cytometry to detect the effect of acetylbufafalin-induced apoptosis in NSCLC cells. NSCLC cells were inoculated in 6-well plates, and after 18 hours of culture, the experimental group was added with different concentrations of acetylbufalin (final concentration was 100nM, 200nM, 400nM), and the control group was added with the same amount of DMSO. Dose-dependent induc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of acetyl bufalin in preparation of antitumor drugs. A structure of the acetyl bufalin is shown as a formula (I), the acetyl bufalin can increase the antineoplastic curative effect, and has good inhibition effect for lung cancer cells.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to the application of acetylbufafalin in the preparation of antitumor drugs. Background technique [0002] Tumor is one of the main causes of human death, and its morbidity and mortality are generally increasing every year. Statistics show that since 2010, malignant tumors have become the leading cause of death among urban and rural residents. It can be seen that the prevention and treatment of tumors is very urgent. Drug therapy is one of the main means of tumor treatment. Although many anti-tumor drugs have been developed, which can effectively prolong the life of patients or improve the quality of life of patients, the research and development of tumor drugs still face great challenges. For example, most anti-tumor drugs are cytotoxic drugs with obvious side effects. The clinical application of these drugs is limited. In the past two decades, targeted therapy for tumors ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/585A61P35/00C07J19/00
CPCA61K31/585A61P35/00C07J19/00
Inventor 赵承光杨乐和戴璇璇项友群周斌胡万乐林士崇赵承伟周潮辉梁广
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap